twoXAR Pharmaceuticals | Pharmaceuticals Discovered with AI

Pharmaceuticals discovered with AI
EFFICIENT DRUG DISCOVERY & DEVELOPMENT
twoXAR Pharmaceuticals is a drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases. twoXAR saves years in drug development while generating a 30x hit rate at in vivo efficacy milestones over traditional methods.
OUR PIPELINE
WEBINAR SERIES
Part 1: SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem
Part 2: VP Discovery, Aaron Daugherty shares how we collaborate with our partners
Part 3: SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR
LATEST NEWS
R&D Is Changing And I'm On Board
Mark Eller, Ph.D.
March 31, 2021
twoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel Chronic Kidney Disease Treatment Candidates
March 4, 2021
My Journey from Skepticism to Conviction Regarding AI
Mark Eller, Ph.D.
February 1, 2021
LATEST EVENTS
WuXi Healthcare Forum 2021
(Digital)
March 15-18, 2021
twoXAR Pharmaceuticals CEO Andrew Radin and SVP of Business Development Allen Poirson host a CEO Roundtable.
3rd Annual CKD3 Summit
CKD3 Summit (Digital)
March 2-4, 2021
twoXAR Pharmaceuticals SVP, Nonclinical R&D & Chemistry Anjali Pandey presents preclinical data of novel treatments for chronic kidney disease
NEWS & EVENTS